1 A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia Diabetes Care 28:1547–1554,

Slides:



Advertisements
Similar presentations
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
Advertisements

ATP III Guidelines Specific Dyslipidemias. 2 Specific Dyslipidemias: Very High LDL Cholesterol (  190 mg/dL) Causes and Diagnosis Genetic disorders –Monogenic.
1. 2 The primary Objective of IDEAL LDL-C Simvastatin mg/d Atorvastatin 80 mg/d risk CHD In stable CHD patients IDEAL: The Incremental Decrease.
IDC 4.1 Problems n High incidence and prevalence of diabetes n Reliance on primary care providers n Significant variation in practice n High costs and.
Oral Medications to Treat Type 2 Diabetes
LDL Cholesterol Goals and Cutpoints for Therapeutic Lifestyle Changes (TLC) and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL)
A Randomised Double-Blind Study of Weight Reducing Effect and Safety of Rimonabant in Obese Patients with or without Comorbidities A Randomised Double-Blind.
P H Y S I C I A N S ’ A C A D E M Y F O R C A R D I O V A S C U L A R E D U C A T I O N Oral drugs for type 2 diabetes and all cause mortality in General.
Diabetes Trials Unit University of Oxford WebSite: Lipids in Diabetes Study.
Comparison of PI vs PI  ATV/r vs DRV/rATADAR. ATV/r 300/100 mg + TDF/FTC qd N = 91 N = 89 DRV/r 800/100 mg + TDF/FTC qd  Design Randomisation 1: 1 Open-label.
Hyperlipidemia Chapter 22. VIDEO There are four principal lipoprotein classes:lipoprotein 1. Chylomicrons are derived from intestinal absorption of exogenous.
Clinical experience with ezetimibe/simvastatin in a Mediterranean population The SETTLE Study I. Migdalis a, A. Efthimiadis b, St. Pappas c, D. Alexopoulos.
Obesity M.A.Kubtan MD - FRCS M.A.Kubtan1. 2  Pulmonary Disease  Fatty Liver Disease  Orthopedic Disorders  Gallbladder Disease  Psychological Impact.
Slide Source: Primary and Other Outcomes: DREAM Rosiglitazone group (n=2635) Placebo group (n=2634)HR (95% CI)p Composite primary.
Criteria for the diagnosis of DM Symptoms of diabetes plus random blood glucose concentration ≥ 200 mg/dl OR FPG ≥ 126 mg/dl OR Two –hour plasma glucose.
By Hussam A.S. Murad and Khaled A. Mahmoud Department of Pharmacology and Therapeutics Faculty of Medicine, Ain Shams University By Hussam A.S. Murad.
Downloaded from Slide 1 Dual Inhibition of Two Sources of Cholesterol: Absorption and Production in Patients with Type 2 Diabetes.
Fenofibrate Intervention and Event Lowering in Diabetes FIELDFIELD Presented at The American Heart Association Scientific Sessions, November 2005 Presented.
Journal Club 2009 年 1 月 29 日(木) 8 : 20 ~ 8 : 50 B 棟 8 階カンファレンスルーム 薬剤部 TTSP 石井 英俊.
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.
A Randomized Placebo- Controlled Trial of Metformin for the Treatment of HIV Lipodystrophy Rakhi Kohli MD MS, Christine Wanke MD, Sherwood Gorbach MD,
ORIGIN Outcome Reduction with an Initial Glargine Intervention (ORIGIN) Trial Overview Large international randomized controlled trial in patients with.
Duality of interests S.Yusuf has received fees for lecturing and research grants from Cadilla Pharma, as well as from 6 other pharma companies that produce.
Copyright® Raisio A plant stanol yogurt drink alone or combined with a low-dose statin lowers serum triacylglycerol and non-HDL cholesterol.
Dyslipidemia.  Dyslipidemia is elevation of plasma cholesterol, triglycerides (TGs), or both, or a low high- density lipoprotein level that contributes.
Rimonabant in Obesity Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Jean-Pierre Despres RIO LIPIDS Trial.
© Copyright 2009 by the American Association for Clinical Chemistry Nonfasting Lipids, Lipoproteins, and Apolipoproteins in Individuals With and Without.
PPAR  activation & lipid metabolism. Diabetic dyslipidaemia Lipid profiles and hyperinsulinaemia in newly diagnosed type 2 diabetic patients Niskanen.
WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.
Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 2 ARBITER-2 Trial Presented at The American Heart Association Scientific.
Clinical Trial Results. org SAGE Trial Prakash Deedwania, MD; Peter H. Stone, MD; C. Noel Bairey Merz, MD; Juan Cosin-Aguilar, MD; Nevres Koylan, MD; Don.
A Diabetes Outcome Progression Trial
Clinical Trial Results. org Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity.
4S: Scandinavian Simvastatin Survival Study
Clinical Trial Results. org METEOR Trial Presented at the American College of Cardiology Annual Scientific Session March, 2007 Presented by Dr. John R.
ACC/AHA Guidelines Not the Final or Only Word. Contemporary Guidelines
Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised,placebo-controlled.
DIABETES INSTITUTE JOURNAL CLUB CARINA SIGNORI, D.O., M.P.H. DECEMBER 15, 2011 Atherothrombosis intervention in metabolic syndrome with low HDL/High Triglycerides:
Lipid profiles in Cardio Vascular Diseases. What is a lipid profile? The lipid profile is a group of tests that are often ordered together to determine.
1 INTRODUCTION Nearly 25% of diabetes patients use insulin Many practitioners: –Are uncomfortable with insulin dosing –Base dosing decisions on empiric.
1 Effect of Ramipril on the Incidence of Diabetes The DREAM Trial Investigators N Engl J Med 2006;355 FM R1 윤나리.
Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease Department of Nephrology R3. Yeehyung Kim.
Changes in the concentration of serum C-peptide in type 2 diabetes during long-term continuous subcutaneous insulin infusion therapy Department of Internal.
Angela Aziz Donnelly April 5, 2016
1 Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled.
R1. 이정미 / prof. 이상열. INTRODUCTION Type 2 diabetes is a major risk factor for cardiovascular disease The presence of both type 2 diabetes and.
The presence of cardiovascular disease is an important predictor of mortality in patients with end-stage renal disease, as it accounts for almost 50 percent.
FOURIER Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Cholesterol-Lowering Ability of a Phytostanol Softgel Supplement in Adults with Mild to Moderate Hypercholesterolemia Woodgate D et al. Lipids. 2006;41:
Arabinda Mohan Bhattarai, MBBS, MD (Biochemistry) Asst Prof, NAIHS
Copyright © 2002 American Medical Association. All rights reserved.
Neal B, et al. Diabetes Care 2015;38:403–411
First time a CETP inhibitor shows reduction of serious CV events
Copyright © 2012 American Medical Association. All rights reserved.
Classification of total cholesterol levels
AIM-HIGH Niacin Plus Statin to Prevent Vascular Events
Updates and Perspectives in Diabetic Dyslipidemia
Sodium-glucose co-transporter 2 (SGLT2) inhibitors work by blocking the reabsorption of filtered glucose in the kidneys. This leads to glucosuria and improved.
Baseline characteristics of HPS participants by prior diabetes
Metabolic Syndrome (N=160) Non-Metabolic Syndrome (N=138) 107/53
Type 2 diabetes: Overlap of clinical conditions
Section 7: Aggressive vs moderate approach to lipid lowering
% decrease in LDL-C at 24 weeks from baseline
Major classes of drugs to reduce lipids
IRIS Trial Insulin Resistance Intervention after Stroke.
Relationship between selected metabolic parameters and the primary composite end point. Relationship between selected metabolic parameters and the primary.
Dyslipidemia And Diabetes
in diabetic patients with mixed dyslipidemia
Section 6: Update on lipid treatment guidelines
Specific Dyslipidemias: Very High LDL Cholesterol (>190 mg/dL)
Presentation transcript:

1 A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia Diabetes Care 28:1547–1554, 2005 R2 박정은

2 Background Type 2 diabetes –relative insulin insufficiency + insulin resistance The dyslipidemia associated with insulin resistance and type 2 diabetes –TG ↑, HDL cholesterol↓ –LDL cholesterol : not increased, small, dense, more atherogeic Increased coronary heart disease

3 Background Thiazolidinedione –Glucose-lowering effect + alter lipid/lipoprotein metabolism –Pioglitazone, rosiglitazone Pioglitazone has differential effects on lipid parameters in patients with type 2 diabetes when compared with rosiglitazone. –Retrospective chart review –Concomitant glucose-lowering and lipid-lowering therapies

4 Objects The lipid and glycemic effects of pioglitazone and rosiglitazone. Pioglitazone has greater triglyceride-lowering effects than rosiglitazone. Multicenter, prospective, randomized, double-blind, parallel group comparison of maximally effective monotherapy doses of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia No concomitant glucose-lowering or lipid-lowering therapies.

5 Methods Subjects –> 35 years of age –Type 2 diabetes –Fasting TG levels : ≥ 150 mg/dL, ≤ 600 mg/dL –Fasting LDL cholesterol : < 130 mg/dL –C-peptide ≥ 1ng/dL –HgA1c : ≥ 7%, ≤ 11% ( no previous OHA ) ≥ 7%, ≤ 9.5% ( previous OHA monotherapy )

6 Methods Subjects : exclusion –insulin –systemic glucocorticoid therapy –combination OHA therapy any lipid- lowering agent –any weight loss agent –known allergy to TZD –Cr ≥ 2 mg/dL –2+ dipstick proteinuria –AST/ALT ↑(1.5 times) –Anemia –NYHA class III,IV –CVD

7 Study design Study design Enrolled patients Current OHA stop Oral placebo 30mg pioglitazone Once daily 4mg rosiglitazone once daily 45mg pioglitazone Once daily 4mg rosiglitazone twice daily 4 weeks 12 weeks

8 Results

9

10

11

12

13

14

15 Discussion The mechanism by which these agents exert differential effects on the lipid profile are not clearly understood. Risk factors for CVD –↑LDL cholesterol, total cholesterol, and triglycerides –↓HDL cholesterol –Primary target : lowering LDL cholesterol

16 Discussion Dyslipidemia of diabetes –TG ↑, HDL cholesterol↓, near normal LDL cholesterol –Insulin resistance : qualitative changes in the composition of LDL cholesterol –LDL particles : decrease in particle size and a greater density of each particle –Increase in TG levels in type 2 diabetes is in part responsible for these atherogenic changes in the LDL profile

17 Discussion Pioglitazone and rosiglitazone differed significantly with opposing effects on triglycerides. Pioglitazone : small, dense → larger, more buoyant LDL : decreased particle concentration Rosiglitazone : ↑LDL particle size, TG levels and LDL particle numbers

18 Discussion Differences in the lipid effects between pioglitazone and rosiglitazone 1.The shift toward larger LDL particles observed with rosiglitazone therapy cannot be due to effects on TG levels. 2.The increase in LDL by pioglitazone – Increased in particle size – Slightly decreased number of LDL particles 3.The increase in LDL by rosiglitazone – Both increased in size and number of LDL

19 Conclusion Pioglitazone and rosiglitazone exert different effects on plasma lipids. Pioglitazone is associated with significant improvements versus rosiglitazone in TG, HDL cholesterol, non-HDL cholesterol, and LDL particle concentrations and LDL particle size. –despite similar effects on glycemic control and surrogate measures of insulin resistance –Whether these differences in lipid effects translate into differences for the risk of CVD is not clear.